Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Tartour

Showing results (31-40 of 227) with videos related to

Pageof 23
Sort By:
Oncoimmunology|July 9, 2015
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaPierre Combe, Eleonore de Guillebon, Constance Thibault, et al.
Traffic (Copenhagen, Denmark)|September 17, 2002
1st class ticket to class I: protein toxins as pathfinders for antigen presentationDaniel C Smith, J Michael Lord, Lynne M Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Revisiting the prognostic value of regulatory T cells in patients with cancerCecile Badoual, Stephane Hans, Wolf H Fridman, et al.
Cancer Research|August 18, 2011
Prognostic and predictive impact of intra- and peritumoral immune infiltratesWolf Herman Fridman, Jérôme Galon, Franck Pagès, et al.
World Journal of Gastroenterology|May 17, 2014
Colorectal cancer and immunity: what we know and perspectivesSimon Pernot, Magali Terme, Thibault Voron, et al.
Vaccine|July 5, 2011
Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subsetMuhammad Suleman, Sandra Galea, Françoise Gavard, et al.
Vaccines|November 10, 2016
Is There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsSoumaya Karaki, Marie Anson, Thi Tran, et al.
Expert Review of Anticancer Therapy|March 20, 2014
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agentsYann-Alexandre Vano, Eric Tartour, Laure S Fournier, et al.
Oncoimmunology|July 4, 2012
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
Head and Neck Pathology|March 4, 2020
The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory TreatmentsSophie Outh-Gauer, Aurélien Morini, Eric Tartour, et al.
Pageof 23

Showing results (31-40 of 227) with videos related to

Sort By:
Pageof 23
Oncoimmunology|July 9, 2015
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaPierre Combe, Eleonore de Guillebon, Constance Thibault, et al.
Traffic (Copenhagen, Denmark)|September 17, 2002
1st class ticket to class I: protein toxins as pathfinders for antigen presentationDaniel C Smith, J Michael Lord, Lynne M Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Revisiting the prognostic value of regulatory T cells in patients with cancerCecile Badoual, Stephane Hans, Wolf H Fridman, et al.
Cancer Research|August 18, 2011
Prognostic and predictive impact of intra- and peritumoral immune infiltratesWolf Herman Fridman, Jérôme Galon, Franck Pagès, et al.
World Journal of Gastroenterology|May 17, 2014
Colorectal cancer and immunity: what we know and perspectivesSimon Pernot, Magali Terme, Thibault Voron, et al.
Vaccine|July 5, 2011
Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subsetMuhammad Suleman, Sandra Galea, Françoise Gavard, et al.
Vaccines|November 10, 2016
Is There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsSoumaya Karaki, Marie Anson, Thi Tran, et al.
Expert Review of Anticancer Therapy|March 20, 2014
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agentsYann-Alexandre Vano, Eric Tartour, Laure S Fournier, et al.
Oncoimmunology|July 4, 2012
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
Head and Neck Pathology|March 4, 2020
The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory TreatmentsSophie Outh-Gauer, Aurélien Morini, Eric Tartour, et al.
Pageof 23